The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 µm showing evidence of self-correction
EuroIntervention 2015;11:204 published online ahead of print February 2015. DOI: 10.4244/EIJY15M02_01
Jens Wiebe1, MD; Timm Bauer1, MD; Oliver Dörr1, MD; Helge Möllmann2, MD; Christian W. Hamm1,2, MD; Holger M. Nef1*, MD
1. Department of Cardiology, Medizinische Klinik I, University of Giessen, Giessen, Germany; 2. Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany
Practical concerns regarding poly-L-lactic acid (PLLA)-based bioresorbable scaffolds (BRS) are mostly related to the strut thickness of 150 µm. Implantation may cause more vessel injury as well as non-laminar flow and activation of platelet function. Furthermore, constraints of deliverability preclude BRS use in the presence of tortuosity or severe calcification. The PLLA-based novolimus-eluting DESolve® 100 scaffold (Elixir Medical Corporation, Sunnyvale, CA, USA) has a strut thickness of 100 µm. Complete degradation is achieved within two years. Furthermore, it has wider expansion ranges than other BRS and self-correction properties corresponding to nominal diameters, which can resolve minor malapposition.